Abstract: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.

Abstract: The present invention relates to novel BR3 binding antibodies having altered Fc effector function and/or having a mature core carbohydrate structure in the Fc region which lacks fiicose. The present invention also relates to the use of those BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.

Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

Abstract: A flow cell for optical detector includes a flow cell body, a face-seal window, and a pressed illumination window. The flow cell body is formed of an inert material and includes large and small bores, and inlet and outlet passageways in fluid communication with the small bore. The face-seal window is affixed within the large area aperture to form a liquid tight seal, while the pressed illumination window is press-set into the small bore. The pressed illumination window is spaced away from the face-seal window to form a sample chamber having a pathlength distance ?. The face-seal window and the pressed window provide an optical path through the sample chamber. Preferably, the flow cell body is formed of PEEK. Methods of forming and using the flow cell are also disclosed.

Abstract: The present invention relates to novel BR3 binding antibodies and polypeptides, including antagonist and agonist polypeptides. The present invention also relates to the use of the BR3 binding antibodies and polypeptides in, e.g., methods of treatment, screening methods, diagnostic methods, assays and protein purification methods.

Abstract: A inert sampling needle is provided for piercing a septum of a vial containing a sample. The sampling needle includes a hollow rigid support member having an inner wall, an outer wall, and a septum-piercing end. The sampling needle also includes a sheath member affixed to the rigid support member. The sheath member covers the septum-piercing end of the support member, the inner wall, and at least a portion of the outer wall adjacent the septum-piercing end to isolate the support member from the sample. Preferably, the sheath member is formed of polyetheretherketone and is affixed to the rigid support member by heat fusing. A method of forming, and a method of using the inert sampling needle is also disclosed.

Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

Abstract: A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as “APBF” has been identified.

Abstract: Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided.

Abstract: A visor clip of unitary construction is presented along with a method for manufacture. The visor clip includes an engagement portion that frictionally engages with an engagement target, which may be a sun visor in an automobile. A payload portion is designed to receive and frictionally couple to a payload, where the payload may include a number of small objects such as toothpicks. The payload portion includes a number of extended portions on one or more of the surfaces that define the payload portion. The inclusion of the extended portions provides a number of force application points that enhance the frictional engagement of the payload.

Abstract: A newly identified heteromeric ligand of the Tumor Necrosis Factor (TNF)-family, referred to hereinafter as “APBF” has been identified.

Abstract: A visor clip of unitary construction is presented along with a method for manufacture. The visor clip includes an engagement portion that frictionally engages with an engagement target, which may be a sun visor in an automobile. A payload portion is designed to receive and frictionally couple to a payload, where the payload may include a number of small objects such as toothpicks. The payload portion includes a number of extended portions on one or more of the surfaces that define the payload portion. The inclusion of the extended portions provides a number of force application points that enhance the frictional engagement of the payload.

Abstract: A low temperature alkali metal electrolysis process for carrying out the electrolysis in the presence of a co-electrolyte and an alkali metal halide. The co-electrolyte comprises (1) a nitrogen-containing compound and optionally one ore more Group IB halides, Group IIIA halides, Group VIII halides; (2) a Group IIIA halide, a Group VB halide, or combinations of a Group IIIA halide and a Group VB halide; or (3) water. Further provided is an electrolyte comprising an alkali metal halide and a co-electrolyte that comprises (1) a nitrogen-containing compound and optionally one ore more Group IB halides, Group IIIA halides, Group VIII halides or (2) a Group IIIA halide, a Group VB halide, or combinations of a Group IIIA halide and a Group VB halide.

Abstract: A process for treatment of hazardous liquid waste comprising trace amounts of hazardous elements in solution as oxyanions by oxyanion fixation within ettringite and related minerals. In accordance with the disclosed process, reagents for forming ettringites are mixed with the waste stream resulting in the formation of oxyanion-substituted ettringite and related materials. The resulting ettringite and related minerals are separated by filtration from the liquid. Thereafter, the liquid, having an elevated pH, is neutralized by carbon dioxide sparging resulting in precipitation of excess reagents in the liquid. Thereafter, the precipitates are filtered, producing a clean liquid.

Abstract: The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains -- a glycoprotein IIb/IIIa inhibitory domain and a thrombin inhibitory domain. The invention also relates to DNA sequences which encode the bifunctional inhibitors of this invention, recombinant DNA molecules which contain these DNA sequences and host transformed with these DNA molecules. The invention further relates to he recombinant expression of the bifunctional inhibitors of this invention by transformed hosts as well as to methods for purifying such recombinant bifunctional inhibitors. This invention also provides compositions and methods employing the novel bifunctional inhibitors alone or together with a fibrinolytic agent.